{"prompt": "['abbvie', 'Rovalpituzumab Tesirine', 'M16-298 Protocol Amendment 4', 'EudraCT 2016-003503-64', 'efficacy endpoint. Major protocol violations will be defined in the SAP prior', 'to the database lock. Subjects will be classified according to treatment', 'assigned at the time of randomization. The per protocol set will be used for', 'supportive analysis of efficacy endpoints.', 'Safety Set: It includes all subjects who received at least one dose of study', 'drug and subjects will be classified according to treatment received. Thus a', 'subject who is randomized to the rovalpituzumab tesirine arm but does not', 'receive rovalpituzumab tesirine will be considered in the placebo arm for', 'safety analysis. Dexamethasone treatment will not be taken into consideration', \"for subjects' classification in the Safety set.\", 'Pharmacokinetic-Evaluable Set: It consists of all subjects who receive at', 'least one dose of study drug, with subjects classified according to the actual', 'treatment received. A baseline measurement and at least one blood sample', 'following a dose of study treatment is required for inclusion in this analysis.', '8.1.1', 'Disposition of Study Subjects', 'The disposition of subjects will be summarized by treatment arm in the randomized set.', 'The subject disposition includes the number of subjects for whom study drug was', 'permanently discontinued (including the reasons for discontinuation), and the number of', 'subjects who discontinued early from the study.', '8.1.2', 'Demographics and Baseline Characteristics', 'Demographic and baseline characteristics will be summarized in the DLL3 high set and', 'randomized set.', '8.1.3', 'Efficacy Endpoints and Analyses', 'Assessment of response and progression will be determined by the CRAC according to', 'RECIST v1.1.', '95']['abbvie', 'Rovalpituzumab Tesirine', 'M16-298 Protocol Amendment 4', 'EudraCT 2016-003503-64', '8.1.4', 'Primary Efficacy Enpoints', 'Progression-free survival (PFS) and overall survival (OS) in subjects with DLL3 high ED', 'SCLC are the two primary efficacy endpoints.', 'PFS will be defined as the number of months from randomization to disease progression,', 'as assessed by the CRAC per RECIST v1.1, or death of any cause, whichever occurs first.', 'Disease progression and censoring rules will be based on published conventions. 15 If a', 'subject neither experienced disease progression nor died, then the data will be censored at', 'the last date of post-baseline radiographic assessment. If a subject with no post-baseline', 'assessment did not experience disease progression nor died, then the data will be censored', 'at the date of randomization.', 'Differences between the treatment arm and the placebo arm in PFS will be assessed by a', 'log-rank test stratified by the randomization stratification factors, testing the null', 'hypothesis (rovalpituzumab tesirine arm is not superior to placebo arm in PFS). The', \"hazard ratios of the treatment arm over the placebo arm will be calculated by a Cox's\", 'proportional hazards regression model adjusting for the main-effects of the stratification', 'factors. Median PFS and 95% confidence intervals will be estimated using Kaplan-Meier', 'survival methodology, with the Kaplan-Meier survival curves presented to provide a', 'visual description. PFS rates at 3, 6, 9, and 12 months after randomization with 95%', 'confidence intervals will be reported. Estimates of the treatment effect will be expressed', 'as hazard ratio including 95% confidence intervals estimated through a Cox proportional-', 'hazards regression model adjusting for the main-effects of the stratification factors.', 'Overall survival will be defined as the number of months from randomization to death of', 'any cause. OS and censoring rules will be based on published conventions. 15 If a subject', 'has not died, the data will be censored at the last date documented to be alive.', 'Differences between the treatment arm and the placebo arm in OS will be assessed by a', 'log-rank test stratified by the randomization stratification factors, testing the null', 'hypothesis (rovalpituzumab tesirine arm is not superior to placebo arm in OS). The', '96']['abbvie', 'Rovalpituzumab Tesirine', 'M16-298 Protocol Amendment 4', 'EudraCT 2016-003503-64', \"hazard ratios of the treatment arm over the placebo arm will be calculated by a Cox's\", 'proportional hazards regression model adjusting for the main-effects of the stratification', 'factors. Median OS and 95% confidence intervals will be estimated using Kaplan-Meier', 'survival methodology, with the Kaplan-Meier survival curves presented to provide a', 'visual description. OS rate at 6, 12, 18, and 24 months and corresponding 95%', 'confidence intervals will be reported. Estimates of the treatment effect on will be', 'expressed as hazard ratio including 95% confidence intervals estimated through Cox', 'proportional-hazards regression models adjusting for the main-effects of the stratification', 'factors.', '8.1.5', 'Secondary Efficacy Endpoints', 'The secondary efficacy endpoints in the randomized set are:', 'os', 'PFS per the CRAC based on RECIST v1.1', 'EORTC QLQ-C30 physical functioning domain', 'Secondary time-to-event endpoints (PFS and OS) will be analyzed using the similar', 'statistical methods described for the primary endpoints.', '8.1.6', 'Exploratory Efficacy Endpoints', 'The exploratory efficacy endpoints in both DLL3 high and randomization set are:', 'Objective response rate (ORR) per the CRAC based on RECIST v1.1', 'PFS per investigator assessment based on RECIST v1.1', 'ORR per investigator assessment based on RECIST v1.1', 'Clinical benefit rate (CBR) per the CRAC and investigator assessment,', 'respectively, based on RECIST v1.1', 'Duration of response (DOR) per CRAC and investigator assessment,', 'respectively', '97']\n\n###\n\n", "completion": "END"}